SRR12202474
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- INTERFERON_ALPHA_RESPONSE+0.450
- G2M_CHECKPOINT+0.260
- SPERMATOGENESIS+0.190
- PANCREAS_BETA_CELLS+0.180
- INTERFERON_GAMMA_RESPONSE+0.170
- FATTY_ACID_METABOLISM+0.160
- MYC_TARGETS_V1+0.160
- DNA_REPAIR+0.130
- OXIDATIVE_PHOSPHORYLATION+0.120
Top 10 suppressed
- ANGIOGENESIS-0.510
- TGF_BETA_SIGNALING-0.430
- ALLOGRAFT_REJECTION-0.410
- NOTCH_SIGNALING-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.350
- WNT_BETA_CATENIN_SIGNALING-0.340
- PI3K_AKT_MTOR_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359410 | — | — | 0.871 |
| 2 | TCGA-E7-A6ME-01A-22R-A32O-07 | — | — | 0.831 |
| 3 | c94686d5.355c.432f.bc98.ccdd30a209de | — | cohortA4 | 0.829 |
| 4 | SRR8943022 | — | — | 0.820 |
| 5 | SRR12202422 | — | — | 0.816 |
| 6 | R320 | — | — | 0.810 |
| 7 | MBCProject_0076_T1_RNA | — | B | 0.808 |
| 8 | TCGA-EW-A1PC-01B-11R-A21T-07 | — | C | 0.806 |
| 9 | SRR26320077 | — | — | 0.804 |
| 10 | TCGA-05-4397-01A-01R-1206-07 | — | cohortA4 | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |